- Home
- AAMI vs NRIX Comparison
AAMI vs NRIX Comparison
Compare AAMI & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AAMI | NRIX |
|---|---|---|
| Founded | 1980 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AAMI | NRIX |
|---|---|---|
| Price | $47.67 | $19.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $43.50 | $26.77 |
| AVG Volume (30 Days) | 231.8K | ★ 1.9M |
| Earning Date | 10-30-2025 | 01-27-2026 |
| Dividend Yield | ★ 0.08% | N/A |
| EPS Growth | ★ 45.00 | N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | ★ $559,300,000.00 | $83,687,000.00 |
| Revenue This Year | $17.88 | $58.38 |
| Revenue Next Year | $21.58 | N/A |
| P/E Ratio | $19.89 | ★ N/A |
| Revenue Growth | 19.25 | ★ 48.32 |
| 52 Week Low | $22.60 | $8.18 |
| 52 Week High | $54.99 | $22.50 |
Technical Indicators
Market Signals| Indicator | AAMI | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 58.08 | 65.22 |
| Support Level | $45.67 | $19.02 |
| Resistance Level | $49.38 | $22.50 |
| Average True Range (ATR) | 1.56 | 1.20 |
| MACD | 0.46 | 0.01 |
| Stochastic Oscillator | 72.45 | 47.53 |
Price Performance
Historical ComparisonAbout AAMI Acadian Asset Management Inc.
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.